ROR1 and soft tissue sarcoma: 22.0405.aF, now named PBA-0405, has recently successfully completed a Phase 0 clinical trial (NCT06273852) as an early proof of concept in ROR1-positive patients with head and neck squamous cell carcinomas and soft tissue sarcomas.